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Thyroid cancer’s incidence has increased dramatically over
the last years and it now accounts for 2.6% of all new
cancers when epithelial skin cancers are excluded. This
increase has been partially attributed to improved screening
methods, mainly ultrasonography identifying subclinical tu-
mors. However, the evidence that also the number of more
advanced tumors and thus thyroid-cancer-associated mor-
tality is increasing suggests that the underlying cause is
not completely understood [1]. The molecular basis of thy-
roid carcinogenesis has been widely investigated, leading to
the discovery of oncogenes such as BRAF, RAS,a n dRET
as major players in tumor development and progression.
Recently, however, it has been shown that the rate of BRAF
mutations that have been associated with a more aggressive
tumor type in papillary thyroid carcinomas has increased
over time [2]. This oncogenic addiction to speciﬁc genetic
changes has highlighted thyroid cancer as an ideal model
for targeted therapy using biological inhibitors and small
molecule inhibitors of RET and BRAF, which have already
reached the clinic [3]. Our ability to detect persistent and
recurrent malignant thyroid tumors has also improved as a
result of more sensitive biochemical tumor marker assays,
although it is unclear whether these higher rates indicate
clinically signiﬁcant disease.
The articles published in this special issue shed new
light on the molecular mechanisms involved in thyroid
tumors and propose novel diagnostic and therapeutic targets
against this disease. The results could have important clinical
ramiﬁcations in the management of patients with thyroid
tumors.
Thyroid follicular neoplasms represent a diagnostic chal-
lenge, as thyroid ﬁne-needle aspiration biopsy cannot distin-
guish benign from malignant tumors in up to 30% of cases.
An important goal would be to identify diagnostic and prog-
nostic markers that could help avoid unnecessary surgeries,
which can result in complications such as recurrent laryngeal
nerve palsy and, in the case of bilateral thyroid surgery,
hypoparathyroidism.Themainpreoperativediagnosticchal-
lenge concerns follicular thyroid lesions. Traditionally, the
distinction between follicular thyroid adenomas and car-
cinomas is made histologically when there is evidence of
capsular and/or vascular invasion. Preoperative markers are,
therefore, sought after. Prabakaran and colleagues analyzed
the expression levels of various genes in archival thyroid
tissue. They found that RAP2A, a member of the ras family
that is closely related to Ras, was signiﬁcantly associated
with higher expression in microdissected carcinoma cells
that have invaded through the thyroid capsule and entered
blood vessels than in thyroid tumor cells growing under the
capsule. They concluded that RAP2A may be a biomarker
associated with invasion of thyroid follicular cells. If their
ﬁnding can be conﬁrmed in larger studies, the evaluation
of this marker in ﬁne-needle aspiration aspirates may be
warranted and informative.2 Journal of Thyroid Research
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the clinical utility of interleukin-8 (IL-8) and interferon-
alpha in the diagnosis of thyroid diseases. IL-8 is a well-
characterized chemotactic cytokine that is produced by ma-
crophages and other cell types such as epithelial cells. Inter-
feron-alpha is an antiviral and anti-proliferative agent that
can stimulate both macrophages and natural killer cells to
elicit an anti-viral response. It has also been shown to be
active against tumors. The authors have analyzed 88 patients
with various types of thyroid diseases. They found overall
increased levels of serum IL-8 in patients with thyroid carci-
noma as compared to various benign disorders. While there
is a large overlap between the serum IL-8 levels in patients
with malignant and benign thyroid diseases, these data
support the idea that chronic inﬂammatory processes may
play an important role in the development and progression
of cancer and provide new therapeutic targets in malignant
thyroid tumors.
Among the novel diagnostic markers proposed in this
issue, M. Hedayati and colleagues report on leptin levels in
83 patients with papillary thyroid and 90 healthy control
persons.Leptinisaneuroendocrinehormonethathasavari-
ety of diﬀerent eﬀects including eﬀects on the immune sys-
tem and the thyroid gland. The authors found signiﬁcantly
higher serum leptin level in patients with thyroid cancer
as compared to the control group including a diﬀerence by
sex.
In another article, l. Giovanella and colleagues have in-
vestigated thyroglobulin as a marker of recurrent or persist-
ent disease by analyzing the levels of thyroglobulin in lymph
nodes in order to analyze the presence of metastatic thyroid
tissue. Thyroglobulin is a protein synthesized by the thyroid
glandandstoredinthefollicularlumen.Since,undernormal
conditions, thyroglobulin can only be found inside the thy-
roid gland, it has been used for decades as a sensitive tumor
marker to detect persistent and recurrent disease in patients
withdiﬀerentiated thyroidcancerof follicularcellorigin (the
most common types of thyroid cancer). Thyroglobulin can,
however, also be used preoperatively to guide the extent of
surgery in patients with persistent or recurrent disease. They
found that thyroglobulin levels higher than 1.1ng/mL in
aspirates from cervical lymph nodes were highly sensitive for
the presence of metastases. Both sensitivity and speciﬁcity
were higher than that of cytology from ﬁne-needle aspirates.
This approach can thus help guide the need and extent
of lymph node dissection in patients who have suspicious
lymph nodes on ultrasound but with inconclusive cytologic
ﬁndings either in the preoperative setting or during follow
up.
Finally, N. Burrows and colleagues report on the role of
hypoxia-inducible factor-1 (HIF-1) in thyroid carcinoma ag-
gressiveness. HIF-1 regulates the expression of several genes
that have been shown to be involved in tumor cell survival,
progression, metastasis, and even resistance to both chem-
otherapy and radiotherapy. In this study, the authors show
that both hypoxia and oncogenic signaling pathways can
induce HIF-1 in thyroid carcinoma. Based on their analysis,
they also suggest that targeting HIF-1 might improve the
poor therapeutic response of advanced thyroid carcinoma to
radiotherapy.
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